Quick Answer
Seres Therapeutics, Inc. reported Operating Income of -$93.97 million for fiscal year 2025.
Seres Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$93.97M | +22.5% |
| 2024 | -$121.31M | +37.8% |
| 2023 | -$195.10M | -8.4% |
| 2022 | -$179.91M | -179.0% |
| 2021 | -$64.49M | +26.8% |
| 2020 | -$88.13M | -22.6% |
| 2019 | -$71.88M | +28.3% |
| 2018 | -$100.28M | -9.7% |
| 2017 | -$91.39M | +1.6% |
| 2016 | -$92.84M | -69.2% |
| 2015 | -$54.86M | -263.7% |
| 2014 | -$15.08M | -149.2% |
| 2013 | -$6.05M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$22.48M | +22.9% | +9.7% |
| June 30, 2025 | -$24.88M | +13.8% | +8.6% |
| March 31, 2025 | -$27.24M | +20.9% | +6.6% |
| September 30, 2024 | -$29.17M | +34.6% | -1.0% |
| June 30, 2024 | -$28.87M | -158.3% | +16.2% |
| March 31, 2024 | -$34.44M | +51.2% | +22.8% |
| September 30, 2023 | -$44.59M | +24.6% | -190.0% |
| June 30, 2023 | $49.52M | +178.2% | +170.2% |
- Seres Therapeutics, Inc. showed an increase of +22.5% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, Seres Therapeutics, Inc.’s operating income has declined by 1452.7% (from -$6.05 million to -$93.97 million).
- The most recent figure is from Seres Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: